D

Dynavax Technologies Corp

DVAX

10.910
USD
-0.28
(-2.50%)
مفتوح الان
حجم التداول
8,489
الربح لكل سهم
0
العائد الربحي
0
P/E
84
حجم السوق
1,434,935,994
أصول ذات صلة
B
BNTX
-5.530
(-6.42%)
80.570 USD
GSK
0.865
(2.23%)
39.650 USD
I
INO
-0.670
(-6.28%)
10.000 USD
JNJ
2.930
(1.86%)
160.770 USD
MRNA
-25.020
(-20.99%)
94.160 USD
N
NVAX
-0.250
(-1.95%)
12.560 USD
PFE
0.115
(0.38%)
30.650 USD
SNY
-0.090
(-0.17%)
51.700 USD
V
VXRT
-0.01170
(-1.74%)
0.65890 USD
الأخبار المقالات

العنوان: Dynavax Technologies Corp

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.